Aug 2026· Biomedicines· Vol 14, pp. 1930· 0 citations· 34 references
Medicine
TL;DR
Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized, and should be interpreted as an adjunct to clinical and radiological assessment.
Abstract
Background/Objectives: Serum cancer antigen 15.3 (CA 15.3) is frequently measured in advanced breast cancer, but its prognostic significance after adjusting for established clinical factors remains incompletely characterized in Latin American populations. We evaluated the association of baseline CA 15.3 with metastatic burden and overall survival (OS) in hormone receptor-positive/HER2-negative advanced breast cancer and descriptively explored baseline/follow-up patterns. Methods: We retrospectively evaluated 127 women treated at a Peruvian public oncology institution between 2018 and 2024, with CA 15.3 levels ≥32.4 U/mL being considered elevated. Baseline associations were assessed using multivariable logistic regression, and OS was evaluated using Kaplan–Meier estimates and Cox proportional hazards regression adjusted for age, ECOG performance status, de novo versus recurrent disease, luminal subtype, first-line treatment, number of metastatic sites, and metastatic site. Results: Baseline CA 15.3 was elevated in 41/127 patients (32.3%) and was independently associated with postmenopausal status (OR: 3.27; 95% CI, 1.33–9.03; p = 0.014) and ≥2 metastatic sites (OR: 2.72; 95% CI, 1.24–6.10; p = 0.013). Median OS was 55 months (95% CI, 43–78), while elevated baseline CA 15.3 was associated with shorter OS (41 vs. 65 months; log-rank p = 0.024) and remained independently associated with shorter OS after multivariable adjustment (adjusted HR: 3.42; 95% CI, 1.63–7.19; p = 0.001). Conclusions: Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized. Thus, CA 15.3 should be interpreted as an adjunct to clinical and radiological assessment.
In this long-term real-world cohort, Mandard TRG was associated with survival, although its prognostic impact appears closely linked to pathological stage and molecular context, particularly in the evolving era of perioperative chemo-immunotherapy.
H. Puhr, B. Mozayani, M. Korpan et al.· ESMO gastrointestinal oncolo...· 0 citations
Background Hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) tumors are the most prevalent subtypes of early breast cancer (eBC). Despite the generally favorable prognosis, a relevant proportion experiences invasive disease events following surgery. We aimed t...
P. Grieger, M. Y. Beykloo, C. Lee et al.· ESMO real world data and dig...· 0 citations
Background/Objectives: The prognostic nutritional index (PNI) has been associated with outcome in metastatic breast cancer, but studies in CDK4/6 inhibitor-treated patients have used cohort-derived thresholds and examined only the pretreatment value. We assessed the PNI as a continuous variable, compared it with inflam...
E. Çoban, A. Kurt, Fırat Akagündüz et al.· Journal of Clinical Medicine· 0 citations
Overall survival in HER2 + EBC has improved over time, reflecting advances in HER2-targeted therapies and comprehensive multimodal treatment strategies.
A. Haidar, Malin Rimskog, Jenny Nyqvist-Streng et al.· Scientific Reports· 0 citations
Gleason score category is independently associated with overall survival and retains prognostic value on the all-cause mortality scale, with greatest discrimination in the years immediately following diagnosis.
The nomograms showed good internal discrimination and may support individualized prognostic assessment once initial treatment information is available, and 5-year estimates should be interpreted cautiously given the median follow-up of 27 months.